Foundation Medicine — 2016 J.P. Morgan Annual Healthcare Conference
22 slides from Foundation Medicine's conference presentation, Jan 11, 2016
Slide 1: 2016 J.P. Morgan Annual Healthcare Conference
2016 J.P. Morgan Annual Healthcare Conference
Slide 2: Forward Looking Statements
These slides and the accompanying oral presentation contain forward-looking statements and information. These materials, including any accompanying oral presentation, contain forward-looking statements about our business. You should not place undue reliance on forward-looking statements as these sta
Slide 3: Who We Are
Who We Are FOUNDATION MEDICINE is a molecular information company that’s leading a transformation in cancer care.
Slide 4: Slide 4
Slide 5: Transformational Shift in Oncology
2012 2016 Little knowledge of immunotherapies in precision medicine Rapid adoption of immunotherapies Cancer is a disease of the anatomy Cancer is a disease of the genome Collaborative basket, umbrella, J.I.T., and community based trials emerge Clinical trials siloed within academia & biopharma 400
Slide 6: Transformational Shift in Oncology
>200 Esoteric Tests >50 FDA Approved Targeted Therapies >500 BioPharmas Developing Targeted Therapies >3,200 Active Clinical Trials >850 Targeted Compounds in Development Unique Patients 1 Brain per Human (even per Oncologist and Pathologist) Transformational Shift in Oncology Data on file
Slide 7: Differentiated and Sustainable Business
Differentiated and Sustainable Business FMI is Embedded into the Fabric of Oncology $12B-15B+ Total addressable market Complete end-to-end solution of innovative molecular diagnostic assays and decision support tools Largest oncology genomics knowledgebase asset Strong balance sheet and operating le
Slide 8: FMI's Molecular Information Business
FMI Assets FMI Stakeholders FMI’s Molecular Information Business FoundationCORETM Physicians Pharma Patients Molecular Information Platform World Class Lab Decision Support Tools Payers
Slide 9: World Class Lab
Premier Lab Deep Expertise in Computational Biology Proprietary Algorithms Unmatched Sensitivity and Specificity World Class Lab Deep Expertise and Unmatched Scale for a Distinct Competitive Advantage
Slide 10: Significant Value Creation from Molecular Information
2010 2011 2012 2013 2014 2015 Largest Aggregation of Validated Oncology Genomic Information 68,000+ Tests FoundationCORE(TM) Knowledgebase Significant Value Creation from Molecular Information
Slide 11: Driving Value through a Portfolio of Unique Decision Support Tools
Driving Value through a Portfolio of Unique Decision Support Tools Extending beyond the clinical test to provide a complete end-to-end solution for optimized delivery of cancer care Physician Patient Payer Pathologist
Slide 12: Increasing Value to Stakeholders through Molecular Information
to BioPharma through Molecular Information Platform for connection to patients for clinical trials Surrogate for patient registries Engine for additional indications and discovery Pathway to a Universal companion diagnostic to Physicians by Enabling a Patient-Centric Approach Streamlined and complet
Slide 13: Patient Need is Large and Unmet
Initial focus for FoundationOne® and FoundationOne® Heme (US unmet need population) ~1.1 million patients $3.5B Patient Need is Large and Unmet Global Addressable Market in 2020: >$15B
Slide 14: Patient Need is Large and Unmet
Initial focus for FoundationOne® and FoundationOne® Heme (US unmet need population) ~1.1 million patients $3.5B Patient Need is Large and Unmet Global Addressable Market in 2020: >$15B Expanded use in U.S. and International ~4 million patients $9B
Slide 15: Patient Need is Large and Unmet
Initial focus for FoundationOne® and FoundationOne® Heme (US unmet need population) ~1.1 million patients $3.5B Patient Need is Large and Unmet Global Addressable Market in 2020: >$15B Expanded use in U.S. and International ~4 million patients $9B $12-15B New Products (e.g., liquid biopsy, monitorin
Slide 16: BioPharma Addressable Market
BioPharma Addressable Market: >$600M Broad Set of Solutions to Accelerate Drug Development More than 25 partners Broad spectrum of trials Enables novel trial designs Enhance patient selection Expand patient populations Enable new targets uniquely identified via FoundationOne >$200M opportunity Molec
Slide 17: Differentiated Programs Extend Market Leadership
Differentiated Programs Extend Market Leadership PATHOLOGISTS Biomarker Testing Team GENENTECH PROGRAMS Drug Access, Financial Assistance and Education PATIENTS Advocacy Programs PAYERS Patient-Oriented Studies Health Economic Data Data Partners ONCOLOGISTS PHARMA CDx Development Molecular Informati
Slide 18: Foundation Medicine is a Growth Story
Foundation Medicine is a Growth Story $ MILLIONS 10.6 29.0 61.1 93.2 2.1
Slide 19: 2015 Financial & Business Highlights
2015 Financial & Business Highlights $93.2M $232M Total revenue, 53% growth year-over-year 32,998 Clinical tests reported, 36% growth year-over-year Cash, cash equivalents and marketable securities Closed transformational $1B+ Roche transaction Palmetto LCD for NSCLC National contract with United He
Slide 20: 2016 Financial Guidance & Business Objectives
2016 Financial Guidance & Business Objectives $110M - $120M $175M - $185M 37,000 - 40,000 Total Revenue Total Operating Expenses Number of F1 & F1 Heme Tests Launch ctDNA commercially in Q1 Submit first FDA PMA for CDx Obtain Medicare payment and broaden national TPP coverage Expand SmartTrials and
Slide 21: Kristen's Story is Foundation Medicine's Story
Kristen’s Story is Foundation Medicine’s Story.
Slide 22: 2016 JP Morgan Annual Healthcare Conference
2016 JP Morgan Annual Healthcare Conference
Foundation Medicine — 2016 J.P. Morgan Annual Healthcare Conference on 6ix